UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39536 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199512 ( State or other jur ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder, and Chief Executive Officer Dr. Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Dr. Frederick Porter - Chief Technical Officer Conference Call Participants Joon Lee - Jo Securities Gil Blum - Needham & Company Mike Ulz - Morgan Stanley Eun Yang - Jefferies Jack Al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-31995 ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session II - President, Founder, and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Company Elizabeth Webster - Goldman Sachs Kevin DeGeeter - Oppenheimer & Company Jack Allen - Baird Yun Zhong - BTIG Laura Chico - Wedbush Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199 ...

Taysha Gene Therapies (NASDAQ:TSHA) Q4 2021 Earnings Conference Call March 31, 2022 8:00 AM ET Company Participants RA Session II – President, Chief Executive Officer & Founder Kimberly Lee – Corporate Affairs Officer Suyash Prasad – Chief Medical Officer & Head, Research & Development Kamran Alam – Chief Financial Officer Conference Call Participants Elizabeth Webster – Goldman Sachs Joon Lee – Truist Securities Mike Ulz – Morgan Stanley Jack Allen – Baird Kevin DeGeeter – Oppenheimer Gil Blum – Needham an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199512 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84- ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2021 Earnings Conference Call November 10, 2021 8:00 AM ET Company Participants Kimberly Lee - SVP, Corporate Communications & IR RA Session II - President, CEO & Founder Suyash Prasad - CMO & Head, R&D Kamran Alam - CFO Conference Call Participants Joon Lee - Truist Securities Gil Blum - Needham and Company Laura Chico - Wedbush Securities Elizabeth Webster - Goldman Sachs Mike Ulz - Morgan Stanley Kevin DeGeeter - Oppenheimer Yun Zhong - BTIG Kristen Kluska - C ...

Bringing New Cures to Life CLN1 Disease Investor Day August 30, 2021 | 9:00 — 11:30 AM CT : 0 . 1 : 1 0 . ： ： ： | ： ● ○ Ⅰ ： ● … : | 0 · ： 0 · | ： ♥ 0 | Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected cos ...